Cytosorbents (CTSO) EBIT Margin (2011 - 2026)
Cytosorbents' (CTSO) quarterly EBIT Margin came in at 27.39% in Q2 2026, up 1020.0% on a YoY basis from 2.45% in Q2 2025, and up 20.26% quarter-over-quarter from 34.34% in Q1 2026.
Powered by 
Analysis
Cytosorbents (CTSO) EBIT Margin (2011 - 2026) Analysis & Trends
Cytosorbents (CTSO) has reported EBIT Margin for 16 consecutive years, with 27.39% the latest figure, recorded in Q2 2026.
- For the quarter ending Q2 2026, EBIT Margin rose 1020.0% year-over-year to 27.39%; the trailing twelve-month figure through Jun 2026 stood at 34.74% (up 882.0% YoY), and the FY2025 full-year result was 39.79%, up 643.0% from the prior year.
- EBIT Margin grew to 27.39% in Q2 2026 per CTSO's latest filing, from 34.34% in the prior quarter.
- Across five years, EBIT Margin topped out at 27.39% in Q2 2026 and bottomed at 111.17% in Q3 2022.
- Historically, EBIT Margin has averaged 62.16% across 5 years, with a median of 53.94% in 2024.
- The sharpest annual moves came in 2022 and 2024: EBIT Margin sank 6273 bps in 2022, then jumped 7144 bps in 2024.
- Over 5 years, EBIT Margin stood at 67.69% in 2022, then tumbled by 60 bps to 108.54% in 2023, then soared by 66 bps to 37.1% in 2024, then decreased by 28 bps to 47.49% in 2025, then jumped by 42 bps to 27.39% in 2026.
- According to Business Quant data, EBIT Margin over the past three periods registered 27.39%, 34.34%, and 47.49% for Q2 2026, Q1 2026, and Q4 2025 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBIT Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 183.04 Bn | 177.44 Bn | 7.27 Bn | 13.44% |
| 2 | Intuitive Surgical | 125.02 Bn | 119.81 Bn | 1.96 Bn | 33.60% |
| 3 | Medtronic | 117.84 Bn | 109.02 Bn | 6.34 Bn | 18.08% |
| 4 | Stryker | 105.50 Bn | 102.02 Bn | 4.50 Bn | 25.18% |
| 5 | Boston Scientific | 66.27 Bn | 65.73 Bn | 3.85 Bn | 21.65% |
| 6 | Edwards Lifesciences | 49.60 Bn | 45.35 Bn | 1.35 Bn | 29.48% |
| 7 | Alcon | 33.70 Bn | 32.24 Bn | 1.68 Bn | 0.40% |
| 8 | Dexcom | 32.06 Bn | 30.11 Bn | 830.00 Mn | 24.33% |
| 9 | Steris | 21.02 Bn | 20.54 Bn | 684.20 Mn | 19.15% |
| 10 | Cytosorbents | 20.00 Mn | 15.59 Mn | 7.05 Mn | -27.39% |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -27.39% |
| Mar 31, 2026 | -34.34% |
| Dec 31, 2025 | -47.49% |
| Sep 30, 2025 | -30.17% |
| Jun 30, 2025 | -37.59% |
| Mar 31, 2025 | -44.55% |
| Dec 31, 2024 | -37.10% |
| Sep 30, 2024 | -56.08% |
| Jun 30, 2024 | -40.38% |
| Mar 31, 2024 | -51.80% |
| Dec 31, 2023 | -108.54% |
| Sep 30, 2023 | -83.42% |
| Jun 30, 2023 | -69.62% |
| Mar 31, 2023 | -83.51% |
| Dec 31, 2022 | -67.69% |
| Sep 30, 2022 | -111.17% |
| Jun 30, 2022 | -98.37% |
| Mar 31, 2022 | -89.64% |
| Dec 31, 2021 | -88.68% |
| Sep 30, 2021 | -55.39% |